Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
As 2016 wraps up. please join us as we look back at our most-viewed articles this year. This week we offer #10-6; we’ll close out the year on the 31st with our top 5. See you in 2017!
#10 FDA Approves First Artificial Pancreas (Oct.)
#9 How Will CGM’s Success Impact Conventional Glucose Monitors? (Guest post by David Kliff, July)
#8 A New Proposed Classification of Diabetes: No More Type 1 or Type 2 Diabetes (Jan.)
#7 Intermittent Fasting and Its Beneficial Effects On The Body (Jan.)
#6 Victoza LEADER Trial Top-Line Results Announced (March)
Letter from the Editor
Over the past year we have provided you with over 850 articles, interviews, best products, snippets of knowledge, tests of knowledge, and educational videos. Each and every week our staff looks over the latest and greatest in diabetes care, and we select what we think you will be most interested in.
As the year draws to the end we are letting you, the readers, select this and next week’s items for publication. Over these two issues we are going to pick the 10 most viewed items and share them with you. As you click through the list you can decide if you remember reading the item, and if it was on your top 10 list.
As an added incentive, if any of you can guess our number one item of the year, we have a special gift for you. All entries must be sent to me at editor@diabetesincontrol.com no later than December 30th.
*****************************
We can make a difference!
*****************************
Dave Joffe, Editor-in-chief
This Week's Survey
What types of Diabetes in Control content do you find most valuable?
1. Information about new studies and treatments
2. Expert opinions/insights (interviews or guest articles)
3. News from conferences (ADA, AACE, etc.)
4. Case studies/personal accounts (for example, Disasters Averted)
5. Other
Follow the link to share your response.
Top Articles of 2016
Device automatically monitors blood glucose levels and delivers insulin when appropriate for people age 14 years and older who have type 1 diabetes.
Guest Post by David Kliff, Diabetic Investor
The FDA approved Dexcom’s request for a non-adjunctive claim this week. It looks like a bad situation for conventional glucose monitors, and believe it or not is about to get worse. Here’s why.
β-cell centric classification of diabetes puts focus on single common denominator of all types.
Old tradition potentially benefits body’s organs, providing possible cure and treatment.
Victoza LEADER trial of 9,000 adults with type 2 diabetes found that drug significantly reduced the risk of heart attack or stroke.